AchondroplasiaCNP C-type natriuretic peptide (CNP) has emerged as a significant therapeutic target for achondroplasia, the most common form of dwarfism.C-type natriuretic peptide co-ordinates cardiac structure and ... Achondroplasia is a genetic disorder characterized by the inhibition of endochondral ossification, leading to disproportionate short stature. Research indicates that CNP plays a crucial role in endochondral ossification, and its analogues are now being developed and approved for treating children with achondroplasia, offering hope for improved growth outcomes.
Achondroplasia arises from mutations in the FGFR3 gene, which disrupt normal bone growth processes. In individuals with achondroplasia, C-type natriuretic peptide plasma levels can be elevated, yet its intracellular activity is suppressed, hindering its normal function in bone development.C-type natriuretic peptide plasma levels are elevated in ... This paradox highlights the complex interplay of signaling pathways involved in the conditionVosoritide - LiverTox - NCBI Bookshelf - NIH.
CNP is a potent stimulator of endochondral ossification, the process by which cartilage is converted into bone. By acting as a signaling molecule, CNP promotes the proliferation and differentiation of chondrocytes, the cells responsible for cartilage formation, which is essential for long bone growth. In preclinical studies, systemic administration of CNP has demonstrated the ability to rescue short stature and impaired bone growth in mouse models of achondroplasia, suggesting its therapeutic potential.
Vosoritide is a biologic analogue of C-type natriuretic peptide that has garnered significant attention for its role in achondroplasia treatment. It is a recombinant C-type natriuretic peptide analogue designed to enhance linear growth in children and adolescents with achondroplasia. Vosoritide has been approved for the treatment of achondroplasia in children, marking a breakthrough in managing this genetic disorderC-Type Natriuretic Peptide Analogue Therapy in Children ....
Clinical trials have shown that vosoritide can increase annualised growth velocity in children with achondroplastic dwarfism作者：DJ Wendt·2015·被引用次数：129—Genetic overexpression of C-type natriuretic peptide (CNP), a positive regulator of endochondral bone growth,prevents dwarfism in mouse models of ACH. However, .... The therapy is administered via daily subcutaneous injections.C-Type Natriuretic Peptide Analog as Therapy for ... While generally well-tolerated, mild side effects such as transient changes in blood pressure have been observed. Ongoing research and clinical trials, such as those assessing vosoritide's pharmacokinetics and exposure-response relationships, continue to refine its application and understanding.
Another promising development in CNP analogue therapy for achondroplasia is TransCon CNP, also known as navepegritide.Achondroplasia Medication: C-Type Natriuretic Peptide This investigational medication is an investigational prodrug of CNP, designed to provide continuous CNP exposure.Vosoritide therapy in children with achondroplasia aged 3− ... Clinical trials, including a Phase 2 trial, have suggested that TransCon CNP is effective and safe, with a low frequency of injection site reactions. Its advantage lies in its potential for once-weekly administration, offering a more convenient dosing regimen compared to daily injections.
The primary benefit of C-type natriuretic peptide analogue therapy, such as with vosoritide and TransCon CNP, is the potential for sustained growth improvements in children with achondroplasia. By targeting the underlying mechanism of impaired endochondral ossification, these therapies aim to address the disproportionate short stature characteristic of the condition作者：EL Schneider·2022·被引用次数：14—The C-natriuretic peptide (CNP) analog vosoritidehas recently been approved for the treatment of achondroplasia in children..
However, several considerations are important. The therapies require regular administration, with vosoritide being a daily subcutaneous injection and TransCon CNP being investigated for once-weekly use. While side effect profiles appear manageable, long-term impacts on comorbidities and adult health outcomes are areas of ongoing study. The development of these therapies represents a significant advancement, moving beyond supportive care to directly address the genetic basis of growth impairment in achondroplasiaTransCon CNP.
The successful development and approval of CNP analogues like vosoritide have opened new avenues for treating achondroplasia. While initially focused on achondroplasia, CNP analogues also hold potential for application in a variety of other growth disorders作者：EL Schneider·2022·被引用次数：13—The C-natriuretic peptide (CNP) analog vosoritidehas recently been approved for treatment of achondroplasia in children. However, the regimen requires .... Continued research into their efficacy, safety, and long-term outcomes will be crucial in optimizing their use and expanding their therapeutic reach作者：EL Schneider·2022·被引用次数：13—The C-natriuretic peptide (CNP) analog vosoritidehas recently been approved for treatment of achondroplasia in children. However, the regimen requires .... The journey from understanding the molecular underpinnings of achondroplasia to developing targeted therapies like C-type natriuretic peptide analogues signifies a major leap forward in pediatric genetics and rare disease treatment.
Join the newsletter to receive news, updates, new products and freebies in your inbox.